+ New Watchlist

Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

Todos Medical

TOMDFOTCEM

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$0.000001

0.000.00%

At close: -

$0.000001

0.000.00%

After Hours: Jun 12, 4:29 PM EDT

Todos Medical (TOMDF) Forecast

News

Earnings Todos Medical (TOMDF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest news for Todos Medical (OTC:TOMDF) Stock

Todos Medical Stock (OTC: TOMDF)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, October 27, 2022

Most Active On The OTC Markets In September – A Look Back As October Comes To A Close
Jad Malaeb - Sponsored

Monday, September 12, 2022

A Quick Look At The OTC Markets' Most-Active Securities In August - Here's What You Need to Know
Jad Malaeb - Sponsored

Thursday, August 11, 2022

Meet The Company Developing Advanved Blood Tests To Detect Cancer And Other Diseases
Jacinta Sherris

Monday, May 02, 2022

Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength including 5 Day Dosing, 30 Day Dosing And 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
Todos Medical - Sponsored

Wednesday, April 27, 2022

Todos Medical Initiates IRB-Waived Tollovid® Market Research Study And Announces 50% Price Reduction Until May 30th, 2022
Todos Medical - Sponsored

Monday, April 25, 2022

Todos Medical To Present At The Emerging Growth Conference
Todos Medical - Sponsored

Thursday, April 21, 2022

Todos Medical Appoints Philippe Goix As Chief Commercial Officer For Provista Diagnostics
Todos Medical - Sponsored

Wednesday, April 20, 2022

Todos Medical Reports 2nd Long COVID Case Study And Launches Website For Physicians And Pediatricians To Indicate Interest In Participating In Tollovid® Long COVID Clinical Study
Todos Medical - Sponsored
Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid® by LGC Group
Todos Medical - Sponsored

Tuesday, April 12, 2022

New Study Reportedly Calls Into Question Merck's Ivermectin COVID Off Label Use And May Bolster 3CL Protease Inhibitors Such As Tollovid
Dana Salzarulo - Sponsored

Wednesday, April 06, 2022

Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate Of Free Sale With Daily And Acute Dosing On The Label
Todos Medical - Sponsored

Monday, April 04, 2022

Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants
Todos Medical - Sponsored
UPDATE: Todos Medical Reports Fourth-Quarter And Full-Year 2021 Financial Results And Corporate Updates
Todos Medical - Sponsored

Friday, April 01, 2022

Todos Medical Reports Fourth-Quarter And Full-Year 2021 Financial Results And Corporate Updates
Todos Medical - Sponsored

Thursday, March 31, 2022

Todos Medical Reports Case Study Of Patient With Long COVID
Todos Medical - Sponsored

Monday, March 28, 2022

Billy Blanks® Endorses Todos Medical's Line Of Tollovid® Products
Todos Medical - Sponsored

Thursday, March 17, 2022

Todos Medical To Present At The Proactive One2One Virtual Forum
Todos Medical - Sponsored

Wednesday, March 16, 2022

Todos Medical Acquires Lucrative NLC Assets For Pennies On The Dollar
Dana Salzarulo - Sponsored
Todos Medical Completes Acquisition Of Key Assets And Intellectual Property From NLC Pharma
Todos Medical - Sponsored

Tuesday, March 15, 2022

Todos Medical To Present At The Emerging Growth Conference
Todos Medical - Sponsored

Tuesday, March 08, 2022

Todos Medical Appoints Greg Meiselbach As Vice President Of Government Affairs
Todos Medical - Sponsored

Monday, February 14, 2022

These OTC Securities Reported The Most Trading Volume In January – With Possible Sustained Interest In International Operators
Jad Malaeb - Sponsored

Friday, January 28, 2022

Abbott Labs Outlook Cools the Omicron Led Testing Boom
Dana Salzarulo - Sponsored

Thursday, January 27, 2022

Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients
Todos Medical - Sponsored

Monday, January 24, 2022

Todos Medical Announces Data Lock in Tollovir™ Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Todos Medical - Sponsored

Wednesday, January 19, 2022

PEPPERDINE UNIVERSITY HOSTS THE 22ND ANNUAL CELEBRITY FLAG FOOTBALL CHALLENGE®, PRESENTED BY TODOS MEDICAL'S TOLLOVID®
Todos Medical - Sponsored

Tuesday, January 18, 2022

Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies
Todos Medical - Sponsored

Wednesday, January 12, 2022

Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022
Todos Medical - Sponsored

Tuesday, January 11, 2022

Todos Medical CEO to Appear on Fox Business to Talk COVID Testing & Tollovir™ on Tuesday, January 11, 2022 and is Presenting at Biotech Showcase 2022
Todos Medical - Sponsored

Monday, January 03, 2022

Todos Medical to Present at January 5, 2022 Emerging Growth Conference
Todos Medical - Sponsored

Wednesday, December 29, 2021

Two Paths to End the Pandemic but the Hybrid Approach Looks Dominant
Dana Salzarulo - Sponsored

Thursday, December 23, 2021

Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer's Paxlovid Approval, Tollovir™ Phase 2 & COVID Testing
Todos Medical - Sponsored

Wednesday, December 22, 2021

Todos Medical Announces New cPass Neutralizing Antibody Testing Reference Lab Agreement for CLIA/CAP Lab Provista with Physician Group in 40 States
Todos Medical - Sponsored
Todos Medical Appoints Valentino Smith, MBA as Vice President of Marketing
Todos Medical - Sponsored

Monday, December 20, 2021

Todos Medical Appoints Valentino Smith, MBA as Vice President of Marketing
Todos Medical - Sponsored

Friday, December 17, 2021

Todos Medical Announces "Test & Tollovid®" Holiday Package for Atlanta Area at Provista Diagnostics
Todos Medical - Sponsored

Thursday, December 16, 2021

Todos Medical to Host Key Opinion Leader Webinar Entitled Tollovir™: a Potential Treatment for Covid-19
Todos Medical - Sponsored

Monday, December 13, 2021

Todos Medical Enters 90-Day Extension of Agreement with Convertible Note Holders on Moratorium on Conversions of Convertible Notes
Todos Medical - Sponsored

Friday, December 10, 2021

Todos Medical Interview and Presentation on Benzinga's All Access Conference Live December 14th at 10:20 AM EST
Todos Medical - Sponsored

Tuesday, December 07, 2021

Todos Medical Announces 2 New COVID-19 PCR Testing Reference Lab Agreements for CLIA/CAP Lab Provista Diagnostics
Todos Medical - Sponsored
Todos Medical to Present at Upcoming Emerging Growth Conference
Todos Medical - Sponsored

Thursday, December 02, 2021

Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation
Todos Medical - Sponsored
Todos Medical to Host Business Update Conference Call on December 2nd at 4:30 PM EST
Todos Medical - Sponsored

Tuesday, November 30, 2021

Todos Medical Confirms SARS-CoV-2 PCR Test Kits Used at CLIA/CAP Lab Provista Diagnostics Detect Omicron Variant
Todos Medical - Sponsored
Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma
Todos Medical - Sponsored

Monday, November 22, 2021

Todos Medical Receives Purchase Order for 50,000 Bottles of Tollovid Daily™ from Its European Distribution Partner T-Cell Protect Hellas S.A for Initial Market Launch in Greece
Todos Medical - Sponsored

Friday, November 19, 2021

Todos Medical Announces Completion of Enrollment for COVID-19 Oral Antiviral 3CLPro (Mpro) Inhibitor Tollovir® Phase 2 Clinical Trial Interim Analysis in Severe and Critical Hospitalized Patients
Todos Medical - Sponsored

Thursday, November 18, 2021

Todos Medical Announces Tollovid® Products Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. Covering 30 Countries in Europe
Todos Medical - Sponsored
Todos Medical Announces Addition of Semi-Quantitative Titer Claims to the Emergency Use Authorization for the cPass Neutralizing Antibody Test
Todos Medical - Sponsored
Todos Medical's Provista Laboratory to Boost Top Line through New Atlanta-based Reference Lab Agreement for COVID PCR, cPass Neutralizing Antibody & Respiratory Pathogen Panel Tests
Todos Medical - Sponsored

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved